Xencor (XNCR) Announces Board Changes

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that Dagmar Rosa-Bjorkeson has informed the Company that she will not stand for reelection to the Company’s Board of Directors at the 2025 Annual Meeting of Stockholders. Ms. Rosa-Bjorkeson has served as a director since 2019 and plans to pursue another business opportunity. Xencor will continue its ongoing process to recruit additional Board members with complementary skillsets.

“On behalf of Xencor's Board of Directors and management team, I want to thank Dagmar for her many contributions to our Board and our audit and nominating and governance committees,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. “Dagmar provided strategic guidance as we have advanced programs and rebalanced our portfolio, and we wish her well in all future endeavors.”

You May Also Be Interested In

• Iran's foreign ministry spokesperson: no talks with the U.S. in coming days
• Verizon falls 7%, AT&T hits 52-week low as SpaceX and cable rivals converge
• Kansas City Capital Downgrades Apogee Enterprises (APOG) to Perform